Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 8, 2014, Pages 912-918

  Bamrah, Sapna ^a   Brostrom, R ^a,b   Dorina, F ^c   Setik, L ^c   Song, R ^a,d   Kawamura, L M ^e   Heetderks, A ^a   Mase, S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b HAWAII STATE DEPARTMENT OF HEALTH   (United States)

^c Deputy Director Public Health   (Federated States of Micronesia)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Multidrug resistant TB; Mycobacterium tuberculosis; TB prevention

Indexed keywords

ETHAMBUTOL; ETHIONAMIDE; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; CHILD; DISEASE COURSE; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEDERATED STATES OF MICRONESIA; FEMALE; HEADACHE; HUMAN; INFECTION PREVENTION; JAUNDICE; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTIDRUG RESISTANT LATENT TUBERCULOUS INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYALGIA; NAUSEA; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL; TUBERCULOSIS CONTROL; YOUNG ADULT; COHORT ANALYSIS; CONTACT EXAMINATION; DIRECTLY OBSERVED THERAPY; EPIDEMIC; INFANT; MICROBIOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONTACT TRACING; DIRECTLY OBSERVED THERAPY; DISEASE OUTBREAKS; FEMALE; FLUOROQUINOLONES; HUMANS; INFANT; LATENT TUBERCULOSIS; MALE; MICRONESIA; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT REFUSAL; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84904577399     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0028     Document Type: Article

References (30)

1. World Health Organization. Global tuberculosis report, 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013.
2. Orenstein E W, Basu S, Shah S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
3. Falzon D, Gandhi N, Migliori G B, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
4. Johnston J C, Shahidi N C, Sadatsafavi M, Fitzgerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLOS ONE 2009; 4: e6914.
5. van Soolingen D, BorgdorffMW, de Haas P E, et al. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 1999; 180: 726-736. (Pubitemid 29411359)
6. Grandjean L, Crossa A, Gilman R H, et al. Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis 2011; 15: 1164-1169.
7. Vella V, Racalbuto V, Guerra R, et al. Household contact investigation of multidrug-resistant and extensively drugresistant tuberculosis in a high HIV prevalence setting. Int J Tuberc Lung Dis 2011; 15: 1170-1175.
8. Iseman M. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-791.
9. Chan E D, Iseman M. Current medical treatment for tuberculosis. BMJ 2002; 325: 1282-1286. (Pubitemid 35430589)
10. Ridzon R, Kent J H, Valway S, et al. Outbreak of drug-resistant tuberculosis with second-generation transmission in a high school in California. J Pediatr 1997; 131: 863-868. (Pubitemid 28027611)
11. Diel R, Loddenkemper R, Zellweger J P, et al; European Forum for TB Innovation. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
12. Ridzon R, Meader J, Maxwell R, et al. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997; 24: 1263-1264.
13. Horn D L, Hewlett D, Alfalla C, Peterson S, Opal SM. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994; 330: 1241. (Pubitemid 24122002)
14. Noel G J, Bradley J S, Kauffman R E, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 2007; 26: 879-891. (Pubitemid 47494159)
15. Passannante M R, Gallagher C T, Reichman L B. Preventative therapy for contacts of multidrug-resistant tuberculosis. Chest 1994; 106: 431-434. (Pubitemid 24252038)
16. Pickwell S M. Positive PPD and chemoprophylaxis for tuberculosis infection. Am Fam Physician 1995; 51: 1929-1934, 1937-1938.
17. Freier G, Wright A, Nelson G, et al. Multidrug-resistant tuberculosis in military recruits. Emerg Infect Dis 2006; 12: 760-762. (Pubitemid 43726848)
18. Gandhi, N, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580. (Pubitemid 44780738)
19. Van Deun A, Maug A K, Salim M A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
20. van der Werf M J, Langendam M W, Sandgren A, Manissero D. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis 2012; 16: 288-296.
21. Centers for Disease Control and Prevention. Reported TB in the United States, 2008: TB surveillance report. Atlanta, GA, USA: CDC, 2011.
22. Centers for Disease Control and Prevention. Two simultaneous outbreaks of multidrug-resistant tuberculosis - Federated States of Micronesia, 2007-2009. MMWR Morb Mortal Wkly Rep 2009; 58: 253-256.
23. Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis. MMWR Morb Mortal Wkly Rep 2005; 41(RR-11): 1-15.
24. National Institutes of Health. Diagnosis of diabetes. National Diabetes Information Clearninghouse. National Institutes of Health Publication No. 09-4642. Bethesda, MD, USA: NIH, 2008.
25. Menzies D, Dion M J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampicin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170: 445-449. (Pubitemid 39214621)
26. Seaworth B. Multidrug-resistant tuberculosis. Infect Dis Clin North Am 2002; 16: 73-105. (Pubitemid 34234945)
27. Brostrom R, Fred D, Heetderks A, et al. Islands of hope: building local capacity to manage an outbreak of multidrug-resistant tuberculosis in the Pacific. Am J Public Health 2011; 101: 14-18.
28. Cain K P, Nelson L J, Cegielski J P. Global policies and practices for managing persons exposed to multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2010; 14: 269-274.
29. Schaaf H S, Gie R P, Kennedy M, Beyers N, Hesseling P B, Donald P R. Evaluation of young children in contact with multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Paediatrics 2002; 109: 765-771. (Pubitemid 34493340)
30. Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005; 54(RR-12): 1-81.